As residents across the southeastern United States face the early impact of Hurricane Florence, CancerCare prepares to offer emotional and financial support to cancer patients impacted by the storm.
The U.S. Senate Sept. 18 passed a conference “minibus” appropriations package that will increase the NIH budget by $2 billion to $39.1 billion—a 5.4 percent boost over the current level.
José Baselga, who has resigned from his positions as physician-in-chief and chief medical officer at Memorial Sloan Kettering Cancer Center, is winding down his research and clinical activities at that institution, officials said.
The European Commission has approved the Novartis agent Kymriah (tisagenlecleucel, formerly CTL019). The approved indications are for the treatment of pediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukemia that is refractory, in relapse post-transplant or in second or later relapse; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Bristol-Myers Squibb Co. said FDA accepted its supplemental Biologics License Application for Empliciti (elotuzumab) in combination with pomalidomide and low-dose dexamethasone for the treatment of patients with relapsed/refractory multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.
Rafael Pharmaceuticals Inc. said FDA has granted an orphan drug designation to CPI-613, the company's lead Altered Energy Metabolism Directed drug candidate, for the treatment of peripheral T-cell lymphoma.
Aslan Pharmaceuticals said FDA has granted ASLAN003 Orphan Drug Designation as a treatment for acute myeloid leukemia.
Novartis said the global phase III SOLAR-1 trial evaluating the investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) has met the primary endpoint showing an improvement in progression-free survival.
In a randomized, phase III trial led by researchers at MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.
In a new study, researchers developed a gene expression predictor that can indicate whether melanoma in a specific patient is likely to respond to treatment with immune checkpoint inhibitors, a novel type of immunotherapy.
